Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo Nordisk could adopt a similar strategy for Wegovy as its CEO is set to testify Sept. 24 before the Senate health committee.
The decision comes in the wake of the company’s updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.
Keytruda is set to continue dominating the sales landscape in 2024 and beyond, but the fast-rising GLP-1 drugs led by Ozempic will reshape the top 10 ranks by the end of the decade.
Entering (and lasting in) the field of healthcare and pharma marketing isn’t easy. The risks are much greater, but so is the reward.
Not many pharmaceuticals become cultural touchstones, but Mounjaro may be the exception.
FCB Health New York’s EQL BAND is the world’s first smartwatch band that uses sound smart technology to accurately hear all heartbeats equally regardless of skin tone. MedAdNews spoke with Kathleen Nanda, FCB Health New York’s chief creative officer, about the device’s development and what brands and agencies can do to support health equity.
MedAdNews spoke with Veeva VP of Strategy Ed Park about his company’s new Compass data product suite.
Fueling experiences with patients, caregivers, and HCPs on their health knowledge journey.
As FDA and other regulatory bodies increasingly accept real-world evidence in drug and biologics submissions for approval, the use of AI can help pharma medical affairs teams more effectively deploy real-world data to generate RWE for supporting physicians and proving the value of products.